Sean Wasserman completed his undergraduate medical degree at the University of Cape Town (UCT) and obtained specialist qualifications in Internal Medicine and Infectious Diseases at the Colleges of Medicine of South Africa. After completing specialist training he undertook full time research towards his PhD at UCT and has worked as a consultant in the Division of Infectious Diseases and HIV Medicine at Groote Schuur Hospital from 2019 to 2023.

Sean joined St Georges as a Reader in Infectious Diseases in the Institute for Infection and Immunity in 2023.

Sean maintains an adjunct appointment as Associate Professor in the Department of Medicine, and is a Principal Investigator at the Centre for Infectious Diseases Research in Africa (CIDRI-Africa), at UCT. He also holds honorary appointments as an Associate Professor at the MRC Centre for Medical Mycology, University of Exeter and as an International Fellow at the Population Health Research Institute, McMaster University.

Sean served as a pharmacologist on the ACTG Tuberculosis Transformative Science Group from 2019 to 2023, and is a member of the NIH-CDC-HIVMA/IDSA Guidelines Committee for Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. He is an Executive Committee Member of the International Society for Infectious Diseases and serves on the ICID 2024 Program Committee.

Sean is the mycobacteriology editor at Antimicrobial Agents and Chemotherapy.

Sean was profiled by the Lancet journal as a ‘rising star in TB-HIV research and medicine’ and has received awards from the International Society for Infectious Diseases, the InterAcademy Partnership, and the International Union against Tuberculosis and Lung Disease.

Clinical interests include management of hospital acquired infection, antimicrobial stewardship, infections in high-risk haematology patients, and management of complicated TB and HIV-associated infections. 

Sean has co-authored two book chapters on HIV-associated TB (in Encyclopedia of AIDS, Springer 2018 and in HIV and Tuberculosis: A Formidable Alliance, Springer 2019) and a chapter on AIDS-related mycosis in which he led the sections on pneumocystis pneumonia and emergomycosis (in Encyclopedia of Mycology. vol. 1, pp. 763–780. Oxford: Elsevier).

Sean has an active programme of clinical research on treatment optimisation for tuberculosis, HIV, and associated opportunistic infections. The overarching goal of his research is to address clinically important questions through translational studies, with an emphasis on reducing infection burden in underserved populations. A primary research focus has been on applying pharmacokinetic analysis to inform dose optimisation of antituberculosis drugs.

Sean is an investigator on several trials of investigational therapeutic approaches for TB and HIV. Current projects include PRESCIENT, a multi-center Phase 2c trial of an ultra-short regimen for drug-susceptible pulmonary TB (NCT05556746); REVIVE, a multi-country Phase 3 trial of azithromycin prophylaxis for advanced HIV (NCT05580666); A5406, an ACTG study evaluating the pharmacokinetics (PK) of double dose dolutegravir with rifapentine-based therapy for HIV-associated TB (NCT05630872); and MR907-2501, an industry-sponsored Phase 2 proof of concept trial of adjunctive rezafungin for HIV-associated pneumocystis pneumonia (NCT05835479).

Other activities include observational cohort studies in HIV-associated infection. Sean leads the pharmacology aspects on an NIH-funded study to understand pathogenesis and optimise therapy in TB meningitis using data from clinical trials and rabbit models. He is a principal investigator in the RePORT SA 3 consortium, leading a cohort study investigating treatment outcome, resistance emergence, and drug exposures as predictors of adherence for drug-resistant TB in the Eastern Cape Province in South Africa. Sean also leads a cohort study to investigate non-invasive diagnostics and treatment response markers for HIV-associated pneumocystis pneumonia in Cape Town.

Wills, N. K., Adriaanse, M., Erasmus, S., & Wasserman, S. (n.d.). Chest X-ray features of HIV-associated Pneumocystis pneumonia (PCP) in adults: a systematic review and meta-analysis. Open Forum Infectious Diseases. doi:10.1093/ofid/ofae146

Hermans, L. E., Booysen, P., Boloko, L., Adriaanse, M., de Wet, T. J., Lifson, A. R., . . . Wasserman, S. (2023). Changing character and waning impact of COVID-19 at a tertiary centre in Cape Town, South Africa.. S Afr J Infect Dis, 38(1), 550. doi:10.4102/sajid.v38i1.550

Scheier, T. C., Youssouf, N., Mosepele, M., Kanyama, C., Adekanmbi, O., Lakoh, S., . . . Wasserman, S. (2023). Standard of care in advanced HIV disease: review of HIV treatment guidelines in six sub-Saharan African countries.. AIDS Res Ther, 20(1), 83. doi:10.1186/s12981-023-00581-5

Lanni, F., Antilus Sainte, R., Hansen, M., Parigi, P., Kaya, F., LoMauro, K., . . . Dartois, V. (2023). A preclinical model of TB meningitis to determine drug penetration and activity at the sites of disease.. Antimicrob Agents Chemother, 67(12), e0067123. doi:10.1128/aac.00671-23

Kimuda, S., Kasozi, D., Namombwe, S., Gakuru, J., Mugabi, T., Kagimu, E., . . . Bahr, N. C. (2023). Advancing Diagnosis and Treatment in People Living with HIV and Tuberculosis Meningitis.. Curr HIV/AIDS Rep, 20(6), 379-393. doi:10.1007/s11904-023-00678-6

Mazanhanga, M., Joubert, A., Castel, S., Van de Merwe, M., Maartens, G., Wasserman, S., & Wiesner, L. (2023). Validation of a quantitative liquid chromatography tandem mass spectrometry assay for linezolid in cerebrospinal fluid and its application to patients with HIV-associated TB-meningitis.. Heliyon, 9(11), e21962. doi:10.1016/j.heliyon.2023.e21962

Brown, T. S., Tang, L., Omar, S. V., Joseph, L., Meintjes, G., Maartens, G., . . . Mathema, B. (2024). Genotype-Phenotype Characterization of Serial Mycobacterium tuberculosis Isolates in Bedaquiline-Resistant Tuberculosis.. Clin Infect Dis, 78(2), 269-276. doi:10.1093/cid/ciad596

Wasserman, S., & Harrison, T. S. (2023). Tuberculous Meningitis - New Approaches Needed.. N Engl J Med, 389(15), 1425-1426. doi:10.1056/NEJMe2310262

Scheier, T. C., Carlin, S., Wills, N. K., Wasserman, S., Mertz, D., & Eikelboom, J. W. (2023). Efficacy and Safety of Intensified vs Standard Prophylactic Anticoagulation Therapy in Patients Hospitalized With Coronavirus Disease 2019: Updated Systematic Review and Meta-analysis.. Open Forum Infect Dis, 10(11), ofad506. doi:10.1093/ofid/ofad506

Boyd, M. J., Mendelson, M., Dlamini, S. K., Wasserman, S., Fakier, G., Roberts, R., & Papavarnavas, N. S. (2023). A case of pericardial schistosomiasis and non-Hodgkin high grade B-cell lymphoma.. S Afr J Infect Dis, 38(1), 524. doi:10.4102/sajid.v38i1.524

Abdelgawad, N., Wasserman, S., Abdelwahab, M. T., Davis, A., Stek, C., Wiesner, L., . . . Denti, P. (2023). Linezolid population pharmacokinetic model in plasma and cerebrospinal fluid among patients with tuberculosis meningitis.. J Infect Dis. doi:10.1093/infdis/jiad413

Patel, K., Sikder, O., Nair, N., Wasserman, S., & Eikelboom, J. W. (2023). Venous Thromboembolism in Patients with Human Immunodeficiency Virus.. TH Open, 7(3), e226-e228. doi:10.1055/a-2110-5884

Arnab, P., Croxford, R., Scott, J., Perumal, S., Mohammed, Z., Wiesner, L., . . . Wasserman, S. (2023). Severe efavirenz associated neurotoxicity: A retrospective cohort study.. S Afr J Infect Dis, 38(1), 522. doi:10.4102/sajid.v38i1.522

Wilkinson, R. J., Donovan, J., Thwaites, G. E., van Crevel, R., & Wasserman, S. (2023). Treatment of tuberculous meningitis: Overdue for concerted action.. Tuberculosis (Edinb), 142, 102361. doi:10.1016/j.tube.2023.102361

Eikelboom, J. W., Belley-Cote, E., Whitlock, R. P., Jolly, S. S., Wasserman, S., Yusuf, S., & ACT Trials Steering Committee. (2023). ACT trials: long-term outcomes.. Lancet Respir Med, 11(6), e50. doi:10.1016/S2213-2600(23)00148-0

Abdelgawad, N., Wasserman, S., Abdelwahab, M. T., Davis, A., Stek, C., Wiesner, L., . . . Denti, P. (2023). Linezolid population pharmacokinetic model in plasma and cerebrospinal fluid among patients with tuberculosis meningitis.. medRxiv. doi:10.1101/2023.04.06.23288230

Stadler, J. A. M., Maartens, G., Meintjes, G., & Wasserman, S. (2023). Clofazimine for the treatment of tuberculosis.. Front Pharmacol, 14, 1100488. doi:10.3389/fphar.2023.1100488

Davies, M. -A., Morden, E., Rousseau, P., Arendse, J., Bam, J. -L., Boloko, L., . . . Boulle, A. (2023). Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 127, 63-68. doi:10.1016/j.ijid.2022.11.024

du Bruyn, E., Stek, C., Daroowala, R., Said-Hartley, Q., Hsiao, M., Schafer, G., . . . Wilkinson, R. J. (2023). Effects of tuberculosis and/or HIV-1 infection on COVID-19 presentation and immune response in Africa.. Nat Commun, 14(1), 188. doi:10.1038/s41467-022-35689-1

Davis, A. G., Wasserman, S., Stek, C., Maxebengula, M., Jason Liang, C., Stegmann, S., . . . Wilkinson, R. J. (2023). A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus-Associated Tuberculous Meningitis: The LASER-TBM Trial.. Clin Infect Dis, 76(8), 1412-1422. doi:10.1093/cid/ciac932

Gatley, E. M., Boyles, T., Dlamini, S., Mendelson, M., Namale, P. E., Raubenheimer, P. J., & Wasserman, S. (2022). Adherence to a care bundle for Staphylococcus aureus bacteraemia: A retrospective cohort study.. S Afr J Infect Dis, 37(1), 445. doi:10.4102/sajid.v37i1.445

Maitre, T., Bonnet, M., Calmy, A., Raberahona, M., Rakotoarivelo, R. A., Rakotosamimanana, N., . . . Bonnet, F. (2022). Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trial.. Trials, 23(1), 928. doi:10.1186/s13063-022-06772-1

Davis, A. G., Dreyer, A. J., Albertyn, C., Maxebengula, M., Stek, C., Wasserman, S., . . . Nightingale, S. (2023). Cognitive Impairment in Tuberculous Meningitis.. Clin Infect Dis, 76(5), 842-849. doi:10.1093/cid/ciac831

Brink, A. J., Coetzee, J., Richards, G. A., Feldman, C., Lowman, W., Tootla, H. D., . . . Mendelson, M. (2022). Best practices: Appropriate use of the new β-lactam/β-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa.. S Afr J Infect Dis, 37(1), 453. doi:10.4102/sajid.v37i1.453

Dangarembizi, R., Wasserman, S., & Hoving, J. C. (2023). Emerging and re-emerging fungal threats in Africa.. Parasite Immunol, 45(2), e12953. doi:10.1111/pim.12953

Eikelboom, J. W., Jolly, S. S., Belley-Cote, E. P., Whitlock, R. P., Rangarajan, S., Xu, L., . . . Yusuf, S. (2022). Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial.. Lancet Respir Med, 10(12), 1169-1177. doi:10.1016/S2213-2600(22)00298-3

Eikelboom, J. W., Jolly, S. S., Belley-Cote, E. P., Whitlock, R. P., Rangarajan, S., Xu, L., . . . Yusuf, S. (2022). Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial.. Lancet Respir Med, 10(12), 1160-1168. doi:10.1016/S2213-2600(22)00299-5

van Beek, S. W., Tanneau, L., Meintjes, G., Wasserman, S., Gandhi, N. R., Campbell, A., . . . Svensson, E. M. (2022). Model-Predicted Impact of ECG Monitoring Strategies During Bedaquiline Treatment.. Open Forum Infect Dis, 9(8), ofac372. doi:10.1093/ofid/ofac372

Parker, A., Boloko, L., Moolla, M. S., Ebrahim, N., Ayele, B. T., Broadhurst, A. G. B., . . . Wasserman, S. (2022). Clinical features and outcomes of COVID-19 admissions in a population with a high prevalence of HIV and tuberculosis: a multicentre cohort study. BMC INFECTIOUS DISEASES, 22(1). doi:10.1186/s12879-022-07519-8

Moosa, M. S., Maartens, G., Gunter, H., Allie, S., Chughlay, M. F., Setshedi, M., . . . Cohen, K. (2022). Rechallenge after anti-tuberculosis drug-induced liver injury in a high HIV prevalence cohort.. South Afr J HIV Med, 23(1), 1376. doi:10.4102/sajhivmed.v23i1.1376

Wills, N. K., Nair, N., Patel, K., Sikder, O., Adriaanse, M., Eikelboom, J., & Wasserman, S. (2022). Efficacy and Safety of Intensified Versus Standard Prophylactic Anticoagulation Therapy in Patients With Coronavirus Disease 2019: A Systematic Review and Meta-Analysis.. Open Forum Infect Dis, 9(7), ofac285. doi:10.1093/ofid/ofac285

Papavarnavas, N. S., Brink, A. J., Dlamini, S., Wasserman, S., Whitelaw, A., Ntusi, N. A. B., & Mendelson, M. (2022). Practice update to optimise the performance and interpretation of blood cultures: 2022. SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 112(6), 397-402. doi:10.7196/SAMJ.2022.v112i6.16537

Davies, M. -A., Kassanjee, R., Rousseau, P., Morden, E., Johnson, L., Solomon, W., . . . Western Cape and South African National Departments of Health in collaboration with the National Institute for Communicable Diseases in South Africa Affiliations. (2022). Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa.. Trop Med Int Health, 27(6), 564-573. doi:10.1111/tmi.13752

Eikelboom, J., Rangarajan, S., Jolly, S. S., Belley-Cote, E. P., Whitlock, R., Beresh, H., . . . Yusuf, S. (2022). The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges.. CJC Open, 4(6), 568-576. doi:10.1016/j.cjco.2022.02.010

Hussey, H., Davies, M. -A., Heekes, A., Williamson, C., Valley-Omar, Z., Hardie, D., . . . Hsiao, N. -Y. (2022). Assessing the clinical severity of the Omicron variant in the Western Cape Province, South Africa, using the diagnostic PCR proxy marker of RdRp target delay to distinguish between Omicron and Delta infections - a survival analysis.. Int J Infect Dis, 118, 150-154. doi:10.1016/j.ijid.2022.02.051

van den Berg, K., Glatt, T. N., Vermeulen, M., Little, F., Swanevelder, R., Barrett, C., . . . Wasserman, S. (2022). Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial).. Sci Rep, 12(1), 2552. doi:10.1038/s41598-022-06221-8

Wasserman, S., Brust, J. C. M., Abdelwahab, M. T., Little, F., Denti, P., Wiesner, L., . . . Maartens, G. (2022). Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study.. J Antimicrob Chemother, 77(4), 1146-1154. doi:10.1093/jac/dkac019

Haas, D. W., Abdelwahab, M. T., van Beek, S. W., Baker, P., Maartens, G., Bradford, Y., . . . Brust, J. C. M. (2022). Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa.. J Infect Dis, 226(1), 147-156. doi:10.1093/infdis/jiac024

Guglielmetti, L., Ardizzoni, E., Atger, M., Baudin, E., Berikova, E., Bonnet, M., . . . Mitnick, C. D. (2021). Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.. Trials, 22(1), 651. doi:10.1186/s13063-021-05491-3

Abdelwahab, M. T., Wasserman, S., Brust, J. C. M., Dheda, K., Wiesner, L., Gandhi, N. R., . . . Denti, P. (2021). Linezolid Population Pharmacokinetics in South African Adults with Drug-Resistant Tuberculosis.. Antimicrob Agents Chemother, 65(12), e0138121. doi:10.1128/AAC.01381-21

Ngwalero, P., Brust, J. C. M., van Beek, S. W., Wasserman, S., Maartens, G., Meintjes, G., . . . Wiesner, L. (2021). Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis.. Antimicrob Agents Chemother, 65(11), e0239920. doi:10.1128/AAC.02399-20

Wasserman, S., Davis, A., Stek, C., Chirehwa, M., Botha, S., Daroowala, R., . . . Wilkinson, R. J. (2021). Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial.. Antimicrob Agents Chemother, 65(8), e0014021. doi:10.1128/AAC.00140-21

Weir, I. R., & Wasserman, S. (2021). Treatment Effect Measures for Culture Conversion Endpoints in Phase IIb Tuberculosis Treatment Trials.. Clin Infect Dis, 73(11), 2131-2139. doi:10.1093/cid/ciab576

Bremer, M., Kadernani, Y. E., Wasserman, S., Wilkinson, R. J., & Davis, A. G. (2021). Strategies for the diagnosis and management of meningitis in HIV-infected adults in resource limited settings.. Expert Opin Pharmacother, 22(15), 2053-2070. doi:10.1080/14656566.2021.1940954

Riou, C., du Bruyn, E., Stek, C., Daroowala, R., Goliath, R. T., Abrahams, F., . . . HIATUS consortium. (2021). Relationship of SARS-CoV-2-specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection.. J Clin Invest, 131(12). doi:10.1172/JCI149125

Davis, A. G., Wasserman, S., Maxebengula, M., Stek, C., Bremer, M., Daroowala, R., . . . Wilkinson, R. J. (2021). Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM].. Wellcome Open Res, 6, 136. doi:10.12688/wellcomeopenres.16783.1

Davis, A. G., Wasserman, S., Maxebengula, M., Stek, C., Bremer, M., Daroowala, R., . . . Wilkinson, R. J. (2021). Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM].. Wellcome open research, 6, 136. doi:10.12688/wellcomeopenres.16783.1

Brust, J. C. M., Gandhi, N. R., Wasserman, S., Maartens, G., Omar, S. V., Ismail, N. A., . . . Meintjes, G. (2021). Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study.. Clin Infect Dis, 73(11), 2083-2092. doi:10.1093/cid/ciab335

Allie, T., Jackson, A., Ambler, J., Johnston, K., Du Bruyn, E., Schultz, C., . . . Tiffin, N. (2021). TBDBT: A TB DataBase Template for collection of harmonized TB clinical research data in REDCap, facilitating data standardisation for inter-study comparison and meta-analyses.. PLoS One, 16(3), e0249165. doi:10.1371/journal.pone.0249165

Boyles, T., Stadelman, A., Ellis, J. P., Cresswell, F. V., Lutje, V., Wasserman, S., . . . Wilkinson, R. (2019). The diagnosis of tuberculous meningitis in adults and adolescents: protocol for a systematic review and individual patient data meta-analysis to inform a multivariable prediction model.. Wellcome Open Res, 4, 19. doi:10.12688/wellcomeopenres.15056.3

Cox, V., McKenna, L., Acquah, R., Reuter, A., Wasserman, S., Vambe, D., . . . Furin, J. (2020). Clinical perspectives on treatment of rifampicin-resistant/multidrug-resistant TB.. Int J Tuberc Lung Dis, 24(11), 1134-1144. doi:10.5588/ijtld.20.0330

Calligaro, G. L., Lalla, U., Audley, G., Gina, P., Miller, M. G., Mendelson, M., . . . Koegelenberg, C. F. N. (2020). The utility of high-flow nasal oxygen for severe COVID-19 pneumonia in a resource-constrained setting: A multi-centre prospective observational study.. EClinicalMedicine, 28, 100570. doi:10.1016/j.eclinm.2020.100570

Mendelson, M., Booyens, L., Boutall, A., Cairncross, L., Calligaro, G., Dave, J. A., . . . Covid-Response Team, O. B. O. T. G. S. H. (2020). The mechanics of setting up a COVID-19 response: Experiences of the COVID-19 epidemic from Groote Schuur Hospital, Cape Town, South Africa.. S Afr Med J, 110(10), 968-972. doi:10.7196/SAMJ.2020.v110i10.15215

Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases, South Africa. (2021). Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa.. Clin Infect Dis, 73(7), e2005-e2015. doi:10.1093/cid/ciaa1198

Mendelson, M., Boloko, L., Boutall, A., Cairncross, L., Calligaro, G., Coccia, C., . . . Schuur Hospital Covid-Response Team, O. B. O. T. G. (2020). Clinical management of COVID-19: Experiences of the COVID-19 epidemic from Groote Schuur Hospital, Cape Town, South Africa.. S Afr Med J, 110(10), 973-981. doi:10.7196/SAMJ.2020.v110i10.15157

Moosa, M. S., Maartens, G., Gunter, H., Allie, S., Chughlay, M. F., Setshedi, M., . . . Cohen, K. (2021). A Randomized Controlled Trial of Intravenous N-Acetylcysteine in the Management of Anti-tuberculosis Drug-Induced Liver Injury.. Clin Infect Dis, 73(9), e3377-e3383. doi:10.1093/cid/ciaa1255

Abdelwahab, M. T., Wasserman, S., Brust, J. C. M., Gandhi, N. R., Meintjes, G., Everitt, D., . . . Denti, P. (2020). Clofazimine pharmacokinetics in patients with TB: dosing implications.. J Antimicrob Chemother, 75(11), 3269-3277. doi:10.1093/jac/dkaa310

Van den Berg, K., Vermeulen, M., Glatt, T. N., Wasserman, S., Barrett, C. L., Peter, J., . . . Louw, V. J. (2020). COVID-19: Convalescent plasma as a potential therapy.. S Afr Med J, 110(7), 562-563. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/32880317

Rohlwink, U. K., Chow, F. C., Wasserman, S., Dian, S., Lai, R. P., Chaidir, L., . . . Tuberculous Meningitis International Research Consortium. (2019). Standardized approaches for clinical sampling and endpoint ascertainment in tuberculous meningitis studies.. Wellcome Open Res, 4, 204. doi:10.12688/wellcomeopenres.15497.2

Wasserman, S., & Furin, J. (2020). Clarity with INHindsight: High-Dose Isoniazid for Drug-Resistant Tuberculosis with inhA Mutations.. Am J Respir Crit Care Med, 201(11), 1331-1333. doi:10.1164/rccm.202002-0264ED

Petersen, E., Wasserman, S., Lee, S. -S., Go, U., Holmes, A. H., Al-Abri, S., . . . Tambyah, P. (2020). COVID-19-We urgently need to start developing an exit strategy.. Int J Infect Dis, 96, 233-239. doi:10.1016/j.ijid.2020.04.035

Petersen, E., Hui, D., Hamer, D. H., Blumberg, L., Madoff, L. C., Pollack, M., . . . Koopmans, M. (2020). Li Wenliang, a face to the frontline healthcare worker. The first doctor to notify the emergence of the SARS-CoV-2, (COVID-19), outbreak.. Int J Infect Dis, 93, 205-207. doi:10.1016/j.ijid.2020.02.052

Wasserman, S., Huo, S., Ky, K., Malig, Y. N., Esmail, A., Dheda, K., . . . Metcalfe, J. (2020). Correlation of Linezolid Hair Concentrations with Plasma Exposure in Patients with Drug-Resistant Tuberculosis.. Antimicrob Agents Chemother, 64(3). doi:10.1128/AAC.02145-19

Cerrone, M., Bracchi, M., Wasserman, S., Pozniak, A., Meintjes, G., Cohen, K., & Wilkinson, R. J. (2020). Safety implications of combined antiretroviral and anti-tuberculosis drugs.. Expert Opin Drug Saf, 19(1), 23-41. doi:10.1080/14740338.2020.1694901

September, J., Geffen, L., Manning, K., Naicker, P., Faro, C., Mendelson, M., & Wasserman, S. (2019). Colonisation with pathogenic drug-resistant bacteria and Clostridioides difficile among residents of residential care facilities in Cape Town, South Africa: a cross-sectional prevalence study.. Antimicrob Resist Infect Control, 8, 180. doi:10.1186/s13756-019-0643-y

Wasserman, S., Davis, A., Wilkinson, R. J., & Meintjes, G. (2019). Key considerations in the pharmacotherapy of tuberculous meningitis.. Expert Opin Pharmacother, 20(15), 1791-1795. doi:10.1080/14656566.2019.1638912

Wasserman, S., Louw, G., Ramangoaela, L., Barber, G., Hayes, C., Omar, S. V., . . . Meintjes, G. (2019). Linezolid resistance in patients with drug-resistant TB and treatment failure in South Africa.. J Antimicrob Chemother, 74(8), 2377-2384. doi:10.1093/jac/dkz206

Otieno-Odhiambo, P., Wasserman, S., & Hoving, J. C. (2019). The Contribution of Host Cells to Pneumocystis Immunity: An Update.. Pathogens, 8(2). doi:10.3390/pathogens8020052

Wasserman, S., Denti, P., Brust, J. C. M., Abdelwahab, M., Hlungulu, S., Wiesner, L., . . . Maartens, G. (2019). Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection.. Antimicrob Agents Chemother, 63(3). doi:10.1128/AAC.02164-18

Walker, N. F., Stek, C., Wasserman, S., Wilkinson, R. J., & Meintjes, G. (2018). The tuberculosis-associated immune reconstitution inflammatory syndrome: recent advances in clinical and pathogenesis research.. Curr Opin HIV AIDS, 13(6), 512-521. doi:10.1097/COH.0000000000000502

Zhao, Y., Fox, T., Manning, K., Stewart, A., Tiffin, N., Khomo, N., . . . Wasserman, S. (2019). Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.. Clin Infect Dis, 68(9), 1522-1529. doi:10.1093/cid/ciy727

Chiliza, N., Du Toit, M., & Wasserman, S. (2018). Outcomes of HIV-associated pneumocystis pneumonia at a South African referral hospital.. PLoS One, 13(8), e0201733. doi:10.1371/journal.pone.0201733

Boyles, T. H., Brink, A., Calligaro, G. L., Cohen, C., Dheda, K., Maartens, G., . . . Federation of Infectious Diseases Societies of Southern Africa. (2018). Erratum to South African guideline for the management of community-acquired pneumonia in adults.. J Thorac Dis, 10(8), E673-E675. doi:10.21037/jtd.2018.07.137

Steinhaus, N., Al-Talib, M., Ive, P., Boyles, T., Bamford, C., Davies, M. -A., . . . Wasserman, S. (2018). The management and outcomes of Staphylococcus aureus bacteraemia at a South African referral hospital: A prospective observational study.. Int J Infect Dis, 73, 78-84. doi:10.1016/j.ijid.2018.06.004

Crombie, K., Spengane, Z., Locketz, M., Dlamini, S., Lehloenya, R., Wasserman, S., . . . Schwartz, I. S. (2018). Paradoxical worsening of Emergomyces africanus infection in an HIV-infected male on itraconazole and antiretroviral therapy.. PLoS Negl Trop Dis, 12(3), e0006173. doi:10.1371/journal.pntd.0006173

Schwartz, I. S., & Wasserman, S. (2017). Itraconazole and antiretroviral therapy: strategies for empirical dosing.. Lancet Infect Dis, 17(11), 1122-1123. doi:10.1016/S1473-3099(17)30568-6

Dheda, K., Cox, H., Esmail, A., Wasserman, S., Chang, K. C., & Lange, C. (2018). Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?. Respirology, 23(1), 36-45. doi:10.1111/resp.13143

Schwartz, I. S., Kenyon, C., Lehloenya, R., Claasens, S., Spengane, Z., Prozesky, H., . . . Dlamini, S. (2017). AIDS-Related Endemic Mycoses in Western Cape, South Africa, and Clinical Mimics: A Cross-Sectional Study of Adults With Advanced HIV and Recent-Onset, Widespread Skin Lesions.. Open Forum Infect Dis, 4(4), ofx186. doi:10.1093/ofid/ofx186

Boyles, T. H., Brink, A., Calligaro, G. L., Cohen, C., Dheda, K., Maartens, G., . . . Federation of Infectious Diseases Societies of Southern Africa. (2017). South African guideline for the management of community-acquired pneumonia in adults.. J Thorac Dis, 9(6), 1469-1502. doi:10.21037/jtd.2017.05.31

Wasserman, S., Potgieter, S., Shoul, E., Constant, D., Stewart, A., Mendelson, M., & Boyles, T. H. (2017). South African medical students' perceptions and knowledge about antibiotic resistance and appropriate prescribing: Are we providing adequate training to future prescribers?. S Afr Med J, 107(5), 405-410. doi:10.7196/SAMJ.2017.v107i5.12370

Boyles, T. H., Gatley, E., Wasserman, S., & Meintjes, G. (2017). Brief Report: Flow Rate of Cerebrospinal Fluid Through a Spinal Needle Can Accurately Predict Intracranial Pressure in Cryptococcal Meningitis.. J Acquir Immune Defic Syndr, 74(3), e64-e66. doi:10.1097/QAI.0000000000001183

McLaren, Z. M., Sharp, A. R., Zhou, J., Wasserman, S., & Nanoo, A. (2017). Assessing healthcare quality using routine data: evaluating the performance of the national tuberculosis programme in South Africa.. Trop Med Int Health, 22(2), 171-179. doi:10.1111/tmi.12819

Madden, R. G., Wallace, S., Sonderup, M., Korsman, S., Chivese, T., Gavine, B., . . . Spearman, C. W. (2016). Hepatitis E virus: Western Cape, South Africa.. World J Gastroenterol, 22(44), 9853-9859. doi:10.3748/wjg.v22.i44.9853

Wasserman, S., Engel, M. E., Griesel, R., & Mendelson, M. (2016). Burden of pneumocystis pneumonia in HIV-infected adults in sub-Saharan Africa: a systematic review and meta-analysis.. BMC Infect Dis, 16(1), 482. doi:10.1186/s12879-016-1809-3

Wasserman, S., Meintjes, G., & Maartens, G. (2016). Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index.. Expert Rev Anti Infect Ther, 14(10), 901-915. doi:10.1080/14787210.2016.1225498

Wasserman, S., Tambyah, P. A., & Lim, P. L. (2016). Yellow fever cases in Asia: primed for an epidemic.. Int J Infect Dis, 48, 98-103. doi:10.1016/j.ijid.2016.04.025

Wasserman, S., & Meintjes, G. (2014). The diagnosis, management and prevention of HIV-associated tuberculosis.. S Afr Med J, 104(12), 886-893. doi:10.7196/samj.9090

Wasserman, S., Engel, M. E., & Mendelson, M. (2013). Burden of pneumocystis pneumonia in HIV-infected adults in sub-Saharan Africa: protocol for a systematic review.. Syst Rev, 2, 112. doi:10.1186/2046-4053-2-112

Boyles, T. H., & Wasserman, S. (2013). Noakes' low-carbohydrate, high-fat diet: call for evidence.. S Afr Med J, 103(12), 882-883. doi:10.7196/samj.7674

Bryer, A., & Wasserman, S. (2013). Thrombolysis for acute ischemic stroke in South Africa.. Int J Stroke, 8 Suppl A100, 112-113. doi:10.1111/ijs.12059

Wasserman, S., & Bryer, A. (2012). Early outcomes of thrombolysis for acute ischaemic stroke in a South African tertiary care centre.. S Afr Med J, 102(6), 541-544. doi:10.7196/samj.5403

Wasserman, S., Vallie, Y., & Bryer, A. (2011). The great pretender.. Lancet, 377(9781), 1976. doi:10.1016/S0140-6736(11)60365-6

Wasserman, S., de Villiers, L., & Bryer, A. (2009). Community-based care of stroke patients in a rural African setting.. S Afr Med J, 99(8), 579-583. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/19908616

Wasserman, S., de Villiers, L., & Bryer, A. (2009). Stroke care in a rural African setting.. Int J Stroke, 4(3), 151. doi:10.1111/j.1747-4949.2009.00275.x

Award: Bill & Melinda Gates Foundation; INV-052110 (Wasserman/Eikelboom). Period: November 2023 - October 2028. Title: Reducing Mortality in Adults with Advanced HIV Disease (REVIVE). Goals: A multi-country randomized placebo-controlled trial to evaluate azithromycin prophylaxis for reducing mortality among people with advanced HIV.

Award: 1U01AI170426 (MPI Koenig/Wasserman). Period: July 2022 - June 2026. Title: PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis. Goals: The major goal of this project is to demonstrate microbiological superiority at 8 weeks for an experimental regimen over standard of care for DS-TB.

Award: NIHR134342 (PI Jarvis/Govender). Period: August 2022 - July 2026. Title: “NIHR Global Health Research Group on HIV-associated Fungal Infections”. Goals: Improve the diagnosis and treatment of HIV-associated fungal infections and ensure that these improvements are made widely available to underserved populations most commonly affected. My role: Work package lead.

Award: 1U01AI152103 (PI Ntsekhe/Wilkinson). Period: May 2020 - April 2025. Title: “Influence of high-dose rifampin on Mycobacterial load and inflammatory mediators in pericardial TB patients”. Goals: Randomized controlled trial of enhanced antibiotic therapy using a novel bacteriological endpoint for pericardial TB. We will use materials collected during the trial to better understand the pathogenesis, how drug treatment helps, and how both the innate and acquired immune responses control bacterial growth or contribute to the syndrome. My role: Co-investigator, pharmacology lead.

Award: R01AI145679 (PI Brust). Period: January 2020 - December 2025. Title: “Emergence of bedaquiline and clofazimine resistance after interruption of drug resistant TB therapy in a high HIV prevalence setting”. Goals: evaluate the impact of treatment interruptions on the development of bedaquiline and clofazimine resistance in TB patients in South Africa. My role: Co-investigator.

Award: R01AI145436 (PI Gengenbacher). Period: March 2020 - February 2025. Title: “Translational approaches to improve understanding and outcome in tuberculous meningitis”. Goals: integrated program of translational and clinical research to develop and validate tools, biomarkers and models, which will help predict disease-induced disability, quantify drug penetration at the site of disease, characterize disease progression, and model response to therapy for TB meningitis.. My role: Co-investigator, pharmacology lead.

Award: 1K43TW011421 (PI Wasserman). Period: May 2019 - April 2024. Title: “Characterizing the pharmacokinetics of high dose rifampicin and linezolid in a randomized controlled trial for HIV-associated tuberculous meningitis”. Goals: Describe PK of intensified antibiotic therapy, evaluate drug-drug interactions, and assess bioavailability of rifampin in TB meningitis.

Award: South African Medical Research Council SHIP grant (PI Meintjes/Wasserman). Period: July 2019 - September 2023. Title: “Determinants of treatment outcomes with an injection-free shorter regimen for MDR/RR-TB.”Goals: prospective cohort study in South Africa to describe outcomes, investigate pyrazinamide resistance, clofazimine toxicity and pharmacokinetics, and treatment adherence in an oral short course regimen for drug-resistant TB.

Award: EDCTP Career Development Fellowship. Period: April 2017 - October 2020. Title: “Optimising linezolid for drug-resistant tuberculosis.” Goals: prospective cohort study to investigate the relationship between linezolid exposure and clinical outcomes in drug-resistant TB.

I have supervised five postgraduate students (four MMed, one MPH) to completion and currently supervise or co-supervise six post-graduate students (two MMed, one MSc, two PhD, one postdoc).